Humacyte posts bigger-than-expected Q4 loss

Overview

• US bioengineered tissue maker's Q4 net income and operating income missed analyst expectations

• Company reported $0.5 mln Q4 revenue, driven by Symvess sales and research collaborations

• Company received $1.475 mln purchase commitment for Symvess clinical evaluation in Saudi Arabia

Outlook

• Company expects top-line interim results from V012 Phase 3 hemodialysis study by early June 2026

• Humacyte plans to submit supplemental BLA for ATEV hemodialysis indication in second half of 2026

• Company aims to begin first-in-human trial for coronary tissue engineered vessel in second half of 2026

Result Drivers

• US LAUNCH - Co said Q4 sales were driven by commercial launch of Symvess in US and growing awareness among surgeons

• INTERNATIONAL INTEREST - $1.475 mln purchase commitment for Symvess clinical evaluation and outreach in Saudi Arabia highlighted international demand

• INVENTORY RESERVE - Co recorded $8.9 mln inventory reserve due to lack of consistent sales history, impacting cost of goods sold and net loss

Company press release: ID:nGNX5PsycG

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Humacyte Inc is $3.50, about 349.6% above its March 26 closing price of $0.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.